Emily Jarvie

4 days ago | proactiveinvestors.com | Emily Jarvie

FinanceBlockchain & Crypto This record is published on behalf of Blockmate Ventures Inc, a paid client of ProactiveAbout this content Disclaimer No investment advice About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022.

4 days ago | proactiveinvestors.com | Emily Jarvie

HealthCannabis This record is published on behalf of Delivra Health Brands Inc., a paid client of ProactiveAbout this content Disclaimer No investment advice About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022.

5 days ago | proactiveinvestors.com | Emily Jarvie

Bit Digital Inc (NASDAQ:BTBT) announced that its wholly-owned high performance computing subsidiary WhiteFiber has acquired a 96-acre industrial property in Madison, North Carolina. The company intends to retrofit the nearly 1 million square foot facility into a flagship AI data center campus. The facility has immediate power availability and is backed by a capacity agreement with Duke Energy for 99 megawatts (MW), with 24 MW expected to be delivered by September 1.

5 days ago | proactiveinvestors.com | Emily Jarvie

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares soared before Monday’s opening bell after it announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company developing psychedelic-based therapies, in an all-share transaction valued at $390 million. The merger is contingent upon the achievement of pre-agreed success criteria in Beckley’s ongoing Phase 2b trial of BPL-003 (mebufotenin benzoate), the company said.

5 days ago | proactiveinvestors.com | Emily Jarvie |Angela Harmantas

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company developing psychedelic-based therapies, in an all-share transaction valued at $390 million. The merger is contingent upon the achievement of pre-agreed success criteria in Beckley’s ongoing Phase 2b trial of BPL-003 (mebufotenin benzoate), the company said.